Literature DB >> 23517784

Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord.

Ellen C Dengler1, Juewen Liu, Audra Kerwin, Sergio Torres, Clara M Olcott, Brandi N Bowman, Leisha Armijo, Katherine Gentry, Jenny Wilkerson, James Wallace, Xingmao Jiang, Eric C Carnes, C Jeffrey Brinker, Erin D Milligan.   

Abstract

Amorphous mesoporous silica nanoparticles ('protocells') that support surface lipid bilayers recently characterized in vitro as carrier constructs for small drug and DNA delivery are reported here as highly biocompatible both in vitro and in vivo, involving the brain and spinal cord following spinal delivery into the lumbosacral subarachnoid space (intrathecal; i.t.). Specifically, positively charged, 1, 2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP)-cholesterol (DOTAP:Chol) liposome-formulated protocells revealed stable in vitro cargo release kinetics and cellular interleukin-10 (IL-10) transgene transfection. Recent approaches using synthetic non-viral vector platforms to deliver the pain-suppressive therapeutic transgene, IL-10, to the spinal subarachnoid space have yielded promising results in animal models of peripheral neuropathy, a condition involving aberrant neuronal communication within sensory pathways in the nervous system. Non-viral drug and gene delivery protocell platforms offer potential flexibility because cargo release-rates can be pH-dependent. We report here that i.t. delivery of protocells, with modified chemistry supporting a surface coating of DOTAP:Chol liposomes and containing the IL-10 transgene, results in functional suppression of pain-related behavior in rats for extended periods. This study is the first demonstration that protocell vectors offer amenable and enduring in vivo biological characteristics that can be applied to spinal gene delivery.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23517784      PMCID: PMC4013798          DOI: 10.1016/j.jconrel.2013.03.009

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  54 in total

1.  Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems.

Authors:  Brian G Trewyn; Supratim Giri; Igor I Slowing; Victor S-Y Lin
Journal:  Chem Commun (Camb)       Date:  2007-03-20       Impact factor: 6.222

Review 2.  Long-term control of neuropathic pain in a non-viral gene therapy paradigm.

Authors:  E M Sloane; R G Soderquist; S F Maier; M J Mahoney; L R Watkins; E D Milligan
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

Review 3.  Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers.

Authors:  Igor I Slowing; Juan L Vivero-Escoto; Chia-Wen Wu; Victor S-Y Lin
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

4.  Inclusion of cholesterol in DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence of serum.

Authors:  K Crook; B J Stevenson; M Dubouchet; D J Porteous
Journal:  Gene Ther       Date:  1998-01       Impact factor: 5.250

5.  Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines.

Authors:  E D Milligan; K A O'Connor; K T Nguyen; C B Armstrong; C Twining; R P Gaykema; A Holguin; D Martin; S F Maier; L R Watkins
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

6.  Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation.

Authors:  Annemarie Ledeboer; Evan M Sloane; Erin D Milligan; Matthew G Frank; John H Mahony; Steven F Maier; Linda R Watkins
Journal:  Pain       Date:  2005-05       Impact factor: 6.961

7.  Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10.

Authors:  Erin D Milligan; Stephen J Langer; Evan M Sloane; Lin He; Julie Wieseler-Frank; Kevin O'Connor; David Martin; John R Forsayeth; Steven F Maier; Kirk Johnson; Raymond A Chavez; Leslie A Leinwand; Linda R Watkins
Journal:  Eur J Neurosci       Date:  2005-04       Impact factor: 3.386

Review 8.  Gene therapy applications for the treatment of neuropathic pain.

Authors:  James R Goss; William F Goins; Joseph C Glorioso
Journal:  Expert Rev Neurother       Date:  2007-05       Impact factor: 4.618

9.  Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro.

Authors:  Eun-Jung Park; Kwangsik Park
Journal:  Toxicol Lett       Date:  2008-10-30       Impact factor: 4.372

10.  Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain.

Authors:  E Sloane; S Langer; B Jekich; J Mahoney; T Hughes; M Frank; W Seibert; G Huberty; B Coats; J Harrison; D Klinman; S Poole; S Maier; K Johnson; R Chavez; L R Watkins; L Leinwand; E Milligan
Journal:  Gene Ther       Date:  2009-07-02       Impact factor: 5.250

View more
  18 in total

Review 1.  Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors.

Authors:  Devan L Puhl; Anthony R D'Amato; Ryan J Gilbert
Journal:  Brain Res Bull       Date:  2019-06-05       Impact factor: 4.077

2.  Chronic Sciatic Neuropathy in Rat Reduces Voluntary Wheel-Running Activity With Concurrent Chronic Mechanical Allodynia.

Authors:  Ryan A Whitehead; Nicholas L Lam; Melody S Sun; Joshua Sanchez; Shahani Noor; Arden G Vanderwall; Timothy R Petersen; Hugh B Martin; Erin D Milligan
Journal:  Anesth Analg       Date:  2017-01       Impact factor: 5.108

3.  In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.

Authors:  Ziqiang Ding; Dujin Wang; Wei Shi; Xiaomei Yang; Siliang Duan; Fengzhen Mo; Xiaoqiong Hou; Aiqun Liu; Xiaoling Lu
Journal:  Int J Nanomedicine       Date:  2020-10-29

4.  Effects of spinal non-viral interleukin-10 gene therapy formulated with d-mannose in neuropathic interleukin-10 deficient mice: Behavioral characterization, mRNA and protein analysis in pain relevant tissues.

Authors:  Arden G Vanderwall; Shahani Noor; Melody S Sun; Jacob E Sanchez; Xuexian O Yang; Lauren L Jantzie; Nikolaos Mellios; Erin D Milligan
Journal:  Brain Behav Immun       Date:  2017-11-04       Impact factor: 7.217

Review 5.  Intrathecal drug delivery in the era of nanomedicine.

Authors:  M J Fowler; J D Cotter; B E Knight; E M Sevick-Muraca; D I Sandberg; R W Sirianni
Journal:  Adv Drug Deliv Rev       Date:  2020-03-03       Impact factor: 15.470

6.  Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.

Authors:  Xiangsheng Liu; Allen Situ; Yanan Kang; Katie Rose Villabroza; Yupei Liao; Chong Hyun Chang; Timothy Donahue; Andre E Nel; Huan Meng
Journal:  ACS Nano       Date:  2016-02-09       Impact factor: 15.881

Review 7.  Gene delivery strategies to promote spinal cord repair.

Authors:  Christopher M Walthers; Stephanie K Seidlits
Journal:  Biomark Insights       Date:  2015-04-09

8.  Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.

Authors:  Huan Meng; Meiying Wang; Huiyu Liu; Xiangsheng Liu; Allen Situ; Bobby Wu; Zhaoxia Ji; Chong Hyun Chang; Andre E Nel
Journal:  ACS Nano       Date:  2015-03-31       Impact factor: 15.881

9.  Mesoporous Silica Nanoparticle-Coated Microneedle Arrays for Intradermal Antigen Delivery.

Authors:  Jing Tu; Guangsheng Du; M Reza Nejadnik; Juha Mönkäre; Koen van der Maaden; Paul H H Bomans; Nico A J M Sommerdijk; Bram Slütter; Wim Jiskoot; Joke A Bouwstra; Alexander Kros
Journal:  Pharm Res       Date:  2017-05-23       Impact factor: 4.200

Review 10.  Mesoporous silica nanoparticles for drug and gene delivery.

Authors:  Yixian Zhou; Guilan Quan; Qiaoli Wu; Xiaoxu Zhang; Boyi Niu; Biyuan Wu; Ying Huang; Xin Pan; Chuanbin Wu
Journal:  Acta Pharm Sin B       Date:  2018-02-12       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.